Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and XELOX in Neoadjuvant Gastric Cancer
NCT04119622Phase 2Unknown
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04119622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119622.